Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
3
×
texas blog main
3
×
texas top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
lung cancer
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
abeona therapeutics
acelity
achaogen
acquisition
affordable care act
allergan
alnylam pharmaceuticals
alzheimer's
amgen
apax partners
arena pharmaceuticals
What
took
3
×
acelity
alzheimer’s
antonio
bio
cancer
company
congress
consortium
democrats
divided
drug
eisai
elections
equity
eyes
fallout
fda
firms
flags
higher
incidence
initial
kinetic
known
lorcaserin
loss
losses
market
marketing
medicine
midterm
offering
panel
patients
plenty
political
post
postpartum
private
Language
unset
Current search:
took
×
" texas blog main "
×
" national blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
San Antonio Wound-Care Company Eyes (Another) Initial Public Offering
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel